Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Investing.com -- GoodRx (NASDAQ: GDRX) stock surged 18% after announcing a collaboration with Novo Nordisk (NYSE: NVO) to offer Ozempic and Wegovy to eligible self-paying patients for $499 per month.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...